Impact Biomedical IBO
NYSE IBO
$0.44 -0.01 (-2.45%)
As of: Aug 21, 2026 · 9:46 AM EDT

Impact Biomedical (IBO) Revenue (2022 - 2026)

Impact Biomedical's (IBO) quarterly Revenue came in at $7000.0 in Q1 2026, down 61.11% on a QoQ basis from $18000.0 in Q3 2025.

Impact Biomedical (IBO) Revenue (2022 - 2026) Analysis & Trends

Impact Biomedical (IBO) has 3 years of Revenue data on file, last reported at $7000.0 in Q1 2026.

  • Quarterly Revenue changed N/A year-over-year to $7000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $32000.0 (changed N/A YoY) and the FY2022 annual result came in at $50000.0, changed N/A from the prior year.
  • Revenue fell to $7000.0 in Q1 2026, from $18000.0 in the prior quarter.
  • In the past five years, Revenue ranged from a high of $50000.0 in Q2 2022 to a low of $7000.0 in Q2 2025.
  • A 3-year average of $20500.0 and a median of $12500.0 in 2025 frame the typical range for Revenue.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Revenue (Qtr)
1 Vertex Pharmaceuticals 138.04 Bn 130.18 Bn 2.84 Bn 3.33 Bn
2 Regeneron Pharmaceuticals 85.98 Bn 77.98 Bn 3.93 Bn 4.29 Bn
3 Argenx Se 64.37 Bn 59.19 Bn 1.37 Bn 1.52 Bn
4 Moderna 57.67 Bn 52.53 Bn 52.00 Mn 145.00 Mn
5 BeOne Medicines 41.94 Bn 36.84 Bn 1.53 Bn 1.71 Bn
6 Alnylam Pharmaceuticals 30.58 Bn 27.27 Bn 992.69 Mn 1.29 Bn
7 BioNTech SE 27.75 Bn 9.35 Bn 668.28 Mn 1.06 Bn
8 Insmed 27.24 Bn 26.08 Bn 358.27 Mn 425.49 Mn
9 Royalty Pharma 27.03 Bn 26.20 Bn - 674.14 Mn
10 Impact Biomedical 47.26 Mn 47.25 Mn 2,000.00 3,000.00

Historic Data

Download Data
DateValue
Jun 30, 2026 3,000.00
Mar 31, 2026 7,000.00
Sep 30, 2025 18,000.00
Jun 30, 2025 7,000.00
Jun 30, 2022 50,000.00